24 results
ARS
2022 FY
PNT
POINT Biopharma Global Inc.
1 May 23
Annual report to shareholders
1:52pm
of manufacturing errors, could result in patient injury or death, product shortages, product recalls or withdrawals, delays or failures in product testing … cannot completely eliminate the risk of contamination or injury resulting from medical or hazardous materials. As a result of any such contamination
8-K
EX-99.2
PNT
POINT Biopharma Global Inc.
12 Sep 22
POINT Biopharma Provides Updated Efficacy and Safety Data from the Lead-In Cohort of the Phase 3 SPLASH Trial in mCRPC at ESMO Congress 2022
7:54am
0.0 0 0.0 Acute kidney injury 0 0.0 0 0.0 1† 3.7 0 0.0 Vomiting 0 0.0 0 0.0 0 0.0 0 0.0 Laboratory abnormalities Lymphocyte count decreased 1 3.7 0 … 0.0 0 0.0 0 0.0 0 0.0 *Includes fatigue and asthenia. †Acute kidney injury leading to hospitalization resolved the following day; this event
DEF 14A
PNT
POINT Biopharma Global Inc.
28 Apr 22
Definitive proxy
8:36am
Federations of Canada National Young Leadership Award of Distinction, the Special Recognition Award by Brain Injury Canada and Bernard Gross Leadership Award
424B3
qk10 wa6qq
31 Mar 22
Prospectus supplement
11:42am
POS AM
f16c20yvss8md23ae4r
25 Mar 22
Prospectus update (post-effective amendment)
8:41am
424B3
vptwsqdh
5 Aug 21
Prospectus supplement
4:26pm
424B3
7aafw3
9 Jun 21
Prospectus supplement
4:42pm
S-4/A
EX-10.16
333v9bmm3s5w5hm
30 Apr 21
Registration of securities issued in business combination transactions (amended)
9:53pm
S-4/A
y2dt24lo
30 Apr 21
Registration of securities issued in business combination transactions (amended)
9:53pm
S-4/A
EX-10.19
k7t8e8
30 Apr 21
Registration of securities issued in business combination transactions (amended)
9:53pm
S-4/A
EX-10.13
xqkly3acrhpdk fz
30 Apr 21
Registration of securities issued in business combination transactions (amended)
9:53pm